Radical cure of experimental cutaneous leishmaniasis by the bisphosphonate pamidronate.
The effects in vivo of the bisphosphonate drug pamidronate, used in bone resorption therapy, were investigated in an experimental model of cutaneous leishmaniasis. Pamidronate at an intraperitoneal dose of 10 mg/kg/day for 5 days effects a radical cure of cutaneous leishmaniasis in Balb/c mice, as evidenced by long-term disappearance of lesions; disappearance of amastigotes in lesion sites, as determined by histopathological analysis and cultivation of material obtained from lesions; and polymerase chain reaction analysis of necropsy material, using probes specific for kinetoplast DNA. Pamidronate is, therefore, a new lead compound for the synthesis of drugs effective against cutaneous leishmaniasis.
Rodriguez
Noris
N
Laboratory of Molecular Parasitology, Department of Pathobiology, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, Illinois 61802, USA.
Bailey
Brian N
BN
Martin
Michael B
MB
Oldfield
Eric
E
Urbina
Julio A
JA
Docampo
Roberto
R
D000818:Animals; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D018105:DNA, Kinetoplast / Q000032:analysis; D004164:Diphosphonates / Q000627:therapeutic use*; D004195:Disease Models, Animal; D007274:Injections, Intraperitoneal; D007894:Leishmania mexicana / Q000235:genetics / Q000302:isolation & purification; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy* / Q000469:parasitology; D051379:Mice; D008807:Mice, Inbred BALB C; D000077268:Pamidronate; D016133:Polymerase Chain Reaction; D013194:Staining and Labeling
D000981:Antiprotozoal Agents; D018105:DNA, Kinetoplast; D004164:Diphosphonates; D000077268:Pamidronate